MedTrace Pharma

  • Booth: 1709

Striving to Make 15O-water Practically Available

MedTrace Pharma is a development stage company working on an automated system for production, injection and analysis of 15O-water PET. 

Based in Denmark, Sweden and the US, we are preparing for the FDA phase III trial (cardiac application) and are in close collaboration with hospitals in the US, Europe and Japan. 

Our solution consists of:

1) the MT-100, which is a point-of-care GMP-compliant chemistry lab combining the process of manufacturing and injecting 15O-water into the patient.

2) the analytical software platform aQuant, that produces unprecedented images combined with quantitative data of the PET scan. 

A double MPI test (rest and stress protocols) can be completed in less than 30 minutes.

Visit our booth at the Small Business Pavilion to learn more about our solution and collaboration opportunities.

Brands: MedTrace Pharma, P3 System (MT-100), 15O-water aQuant


MedTrace SNMMI video

 Press Releases

  • MedTrace Pharma A/S announced today the FDA approval of the company’s Investigational New Drug (IND) application and the approval to commence the RAPID-WATER clinical trial to evaluate the use of 15O-water PET in diagnosing Coronary Artery Disease (CAD). The global trial will enroll adults with suspected CAD.


  • As part of the recently closed equity fundraising, MedTrace also signed a know-how license agreement with Mayo Clinic (Rochester, MN, USA) embarking on the already installed P3 prototype and the aQuant software.

    The scope of the agreement is outlined in the press release below.


  • The first PET scans with 15O-water generated with a novel production and administration system from the Danish company MedTrace Pharma A/S (MedTrace) have been performed in patients at Aarhus University Hospital (AUH).  AUH has become the first hospital in the world to utilize, under a magistral exemption, a clinical system that makes the use of 15O-water PET practical and efficient.  As many as 1500 patients suspected to have coronary artery disease (CAD) pr. year are expected to be imaged at AUH with this approach in a rest/stress scan protocol.


For Technical Support with this webpage, please contact support.